Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5489-5503

  Lee, Sang Joon ^a   Jeong, Young Il ^b   Park, Hyung Kyu ^a   Kang, Dae Hwan ^b,c   Oh, Jong Suk ^a   Lee, Sam Gyu ^a   Lee, Hyun Chul ^a  

^a Chonnam National University Medical School   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Cathepsin B; CT26 cell; Enzyme sensitive dendrimer; Tetra peptide; Tumor targeting

Indexed keywords

CATHEPSIN B; CYANAMIDE; DENDRIMER; DOXORUBICIN; GLYCYLPHENYLALANYLLEUCYLGLYCINE; MACROGOL; NANOPARTICLE; TETRAPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBODIIMIDE BINDING PROTEINS; CARRIER PROTEIN; GLY-PHE-LEU-GLY; MACROGOL DERIVATIVE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADATION; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; NEOPLASMS; PARTICLE SIZE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CATHEPSIN B; CELL LINE, TUMOR; DENDRIMERS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; MICE; NANOPARTICLES; NEOPLASMS; OLIGOPEPTIDES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940662121     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S87145     Document Type: Article

References (33)

1. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–672
2. McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014;371:1725–1735
3. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16:253–262
4. Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs. Part 1. Cytotoxics. Eur J Cancer. 2014;50: 2010–2019
5. Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs. Part two – targeted therapies. Eur J Cancer. 2014;50:2020–2036
6. Marchetti C, Palaia I, Giorgini M, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther. 2014; 7:1223–1236
7. McCrudden CM, McCarthy HO. Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet. 2014;7:209–220
8. Ryan SM, Brayden DJ. Progress in the delivery of nanoparticle constructs: towards clinical translation. Curr Opin Pharmacol. 2014; 18C:120–128
9. Kajimoto K, Sato Y, Nakamura T, Yamada Y, Harashima H. Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo. J Control Release. 2014;190: 593–606
10. Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release. 2014; 190:451–464
11. Cho HY, Lee YB. Nano-sized drug delivery systems for lymphatic delivery. J Nanosci Nanotechnol. 2014;14:868–880
12. Orza A, Casciano D, Biris A. Nanomaterials for targeted drug delivery to cancer stem cells. Drug Metab Rev. 2014;46:191–206
13. Hubbell JA, Chikoti A. Nanomaterials for drug delivery. Science. 2012; 337:303–305
14. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159
15. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol. 2011;63:141–163
16. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release. 2014;190:465–476
17. Zhao Y, Lin D, Wu F, et al. Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery. Int J Mol Sci. 2014;15:17565–17576
18. Jeong YI, Kim YW, Jung S, et al. Delivery of transferrin-conjugated polysaccharide nanoparticles in 9L gliosarcoma cells. J Nanosci Nanotechnol. 2015;15:125–129
19. Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9:247
20. Jain K, Jain NK. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer. J Nanosci Nanotechnol. 2014;14:5075–5087
21. Lyulin SV, Vattulainen I, Gurtovenko AA. Complexes comprised of charged dendrimers, linear polyelectrolytes, and counterions: insight through coarse-grained molecular dynamics simulations. Macromolecules. 2008;41:4961–4968
22. Eleftheriou E, Karatasos K. Modeling the formation of ordered nanoassemblies comprised by dendrimers and linear polyelectrolytes: the role of Coulombic interactions. J Chem Phys. 2012;137:144905
23. Yang R, Xia S, Ye T, et al. Synthesis of a novel polyamidoamine dendrimer conjugating with alkali blue as a lymphatic tracer and study on the lymphatic targeting in vivo. Drug Deliv. November 19, 2014. [Epub ahead of print]
24. He X, Alves CS, Oliveira N, et al. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. Colloids Surf B Biointerfaces. 2015;125:82–89
25. Kaminskas LM, Kelly BD, McLeod VM, et al. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. Mol Pharm. 2011;8:338–349
26. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem. 2003;384:447–455
27. Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol. 2013;72:417–427
28. Chen Z, Zhang P, Cheetham AG, et al. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release. 2014;191:123–130
29. Maniganda S, Sankar V, Nair JB, Raghu KG, Maiti KK. A lysosometargeted drug delivery system based on sorbitol backbone towards efficient cancer therapy. Org Biomol Chem. 2014;12:6564–6569.
30. Alencar H, Funovics MA, Figueiredo J, Sawaya H, Weissleder R, Mahmood U. Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection – study in mice. Radiology. 2007; 244:232–238
31. Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Peyrat JP. Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Cancer Lett. 1995;96:267–275
32. Kuester D, Lippert H, Roessner A, Krueger S. The cathepsin family and their role in colorectal cancer. Pathol Res Pract. 2008;204:491–500
33. Funovics MA, Alencar H, Montet X, Weissleder R, Mahmood U. Simultaneous fluorescence imaging of protease expression and vascularity during murine colonoscopy for colonic lesion characterization. Gastrointest Endosc. 2006;64:589–597.